David S Hong1, Steven G DuBois2, Shivaani Kummar3, Anna F Farago4, Catherine M Albert5, Kristoffer S Rohrberg6, Cornelis M van Tilburg7, Ramamoorthy Nagasubramanian8, Jordan D Berlin9, Noah Federman10, Leo Mascarenhas11, Birgit Geoerger12, Afshin Dowlati13, Alberto S Pappo14, Stefan Bielack15, François Doz16, Ray McDermott17, Jyoti D Patel18, Russell J Schilder19, Makoto Tahara20, Stefan M Pfister21, Olaf Witt7, Marc Ladanyi22, Erin R Rudzinski23, Shivani Nanda24, Barrett H Childs24, Theodore W Laetsch25, David M Hyman26, Alexander Drilon27. 1. University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA. 3. Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA. 4. Massachusetts General Hospital, Boston, MA, USA. 5. Seattle Children's Hospital, University of Washington, Seattle, WA, USA. 6. Rigshospitalet, Copenhagen University, Copenhagen, Denmark. 7. Hopp Children's Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany. 8. Nemours Children's Hospital, Orlando, FL, USA. 9. Vanderbilt University Medical Center, Nashville, TN, USA. 10. David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. 11. Saban Research Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 12. Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France. 13. University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 14. St Jude Children's Research Hospital, Memphis, TN, USA. 15. Klinikum Stuttgart-Olgahospital, Stuttgart Cancer Center, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany. 16. SIREDO Center Care, Innovation, Research In Pediatric, Adolescent and Young Adult Oncology, Institut Curie and Paris Descartes University, Paris, France. 17. St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland. 18. University of Chicago, Chicago, IL, USA. 19. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA. 20. National Cancer Center Hospital East, Kashiwa, Japan. 21. Hopp Children's Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany; German Cancer Network, Heidelberg, Germany. 22. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 23. Seattle Children's Hospital, Seattle, WA, USA. 24. Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA. 25. University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, USA. 26. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. 27. Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: drilona@mskcc.org.
Abstract
BACKGROUND: The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours. METHODS: Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting). FINDINGS: Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred. INTERPRETATION: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible. FUNDING: Bayer and Loxo Oncology.
BACKGROUND: The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours. METHODS:Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting). FINDINGS: Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred. INTERPRETATION: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible. FUNDING: Bayer and Loxo Oncology.
Authors: Alexander Drilon; Sai-Hong Ignatius Ou; Byoung Chul Cho; Dong-Wan Kim; Jeeyun Lee; Jessica J Lin; Viola W Zhu; Myung-Ju Ahn; D Ross Camidge; Judy Nguyen; Dayong Zhai; Wei Deng; Zhongdong Huang; Evan Rogers; Juliet Liu; Jeff Whitten; John K Lim; Shanna Stopatschinskaja; David M Hyman; Robert C Doebele; J Jean Cui; Alice T Shaw Journal: Cancer Discov Date: 2018-08-09 Impact factor: 39.397
Authors: Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman Journal: N Engl J Med Date: 2018-02-22 Impact factor: 91.245
Authors: Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok Journal: N Engl J Med Date: 2017-06-06 Impact factor: 91.245
Authors: Cristina Tognon; Stevan R Knezevich; David Huntsman; Calvin D Roskelley; Natalya Melnyk; Joan A Mathers; Laurence Becker; Fatima Carneiro; Nicol MacPherson; Doug Horsman; Christopher Poremba; Poul H B Sorensen Journal: Cancer Cell Date: 2002-11 Impact factor: 31.743
Authors: Alena Skálová; Tomas Vanecek; Radek Sima; Jan Laco; Ilan Weinreb; Bayardo Perez-Ordonez; Ivo Starek; Marie Geierova; Roderrick H W Simpson; Fabricio Passador-Santos; Ales Ryska; Ilmo Leivo; Zdenek Kinkor; Michal Michal Journal: Am J Surg Pathol Date: 2010-05 Impact factor: 6.394
Authors: Robert C Doebele; Lara E Davis; Aria Vaishnavi; Anh T Le; Adriana Estrada-Bernal; Stephen Keysar; Antonio Jimeno; Marileila Varella-Garcia; Dara L Aisner; Yali Li; Philip J Stephens; Deborah Morosini; Brian B Tuch; Michele Fernandes; Nisha Nanda; Jennifer A Low Journal: Cancer Discov Date: 2015-07-27 Impact factor: 39.397
Authors: Amir Momeni-Boroujeni; Nissreen Mohammad; Robert Wolber; Stephen Yip; Martin Köbel; Brendan C Dickson; Martee L Hensley; Mario M Leitao; Cristina R Antonescu; Ryma Benayed; Marc Ladanyi; Cheng-Han Lee; Sarah Chiang Journal: Mod Pathol Date: 2020-10-19 Impact factor: 7.842